MedTrace Logo

Dexmedetomidine and Agitation After Nasal Surgery

NCT06867302 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-03-10

No results posted yet for this study

Summary

The main objective of study is to compare dexmedetomidine single bolus dose before extubation with continuous infusion as regards their efficacy in mitigating the incidence of emergence agitation in obese adults undergoing nasal surgery.

Conditions

  • Nasal Disease
  • Agitation, Emergence

Interventions

DRUG

Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)

An infusion given all through intraoperative time

DRUG

Dexmedetomidine Injection [Precedex]

Single dose given 15 minutes before end of surgery

Sponsors & Collaborators

  • Fayoum University Hospital

    lead OTHER

Principal Investigators

  • Yasser S Mostafa, MD · Fayoum University

  • Mohamed A Shawky, MD · Fayoum University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-09-01
Completion
2025-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06867302 on ClinicalTrials.gov